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ttp://dx.doi.org/10.1016/j.jmoldx.2013.07.002Recurrent mutations in JAK2 and MPL genes are genetic hallmarks of BCR-ABL1enegative myelopro-
liferative neoplasms. Detection of JAK2 and MPL mutations has been incorporated into routine diag-
nostic algorithms for these diseases. This Special Article summarizes results from a nationwide
laboratory survey of JAK2 and MPL mutation analysis. Based on the current practice pattern and the
literature, this Special Article provides recommendations and guidelines for laboratory practice for
detection of mutations in the JAK2 and MPL genes, including clinical manifestations for prompting the
mutation analysis, current and recommended methodologies for testing the mutations, and stan-
dardization for reporting the test results. This Special Article also points to future directions for
genomic testing in BCR-ABL1enegative myeloproliferative neoplasms. (J Mol Diagn 2013, 15: 733e744;
http://dx.doi.org/10.1016/j.jmoldx.2013.07.002)Supported by the Association for Molecular Pathology.
The JAK2MutationWorkingGroup is aworking group of theAssociation for
Molecular Pathology (AMP)Clinical PracticeCommittee. The2012e2013AMP
Clinical Practice Committee consisted of Matthew J. Bankowski, Milena Can-
kovic, Jennifer Dunlap, Larissa V. Furtado, Jerald Z. Gong, Cyrus V. Hedvat,
Thomas Huard, Linda Jeng, Loren Joseph (Chair, 2013), Marilyn M. Li, Janina
Longtine (Chair, 2012),KathleenT.Montone,PaulRothberg, andSibySebastian.
Standard of practice is not deﬁned by this article, and there may be
alternatives. See Disclaimer for further details.
Current address of Y.L.W., Department of Pathology, University of
Chicago, Chicago, IL.In 2005, several groups simultaneously described a point
mutation in codon 617 of the protein tyrosine kinase gene
Janus kinase 2 (JAK2) in BCR-ABL1enegative myelopro-
liferative neoplasms (MPN). This mutation was found in the
vast majority of patients with polycythemia vera (PV) and in
approximately half of patients with essential thrombocythe-
mia (ET) or primary myeloﬁbrosis (PMF).1e4 In 2007,
additional mutations in exon 12 of JAK2 gene were found in a
small percentage of PV patients.5 The exon 12 mutations and
the V617F mutation are mutually exclusive; either V617F orstigative Pathology
.
Gong et alexon 12 mutations are present in virtually all cases of PV. In
2006, mutations in a second gene, myeloproliferative
leukemia virus oncogene (MPL), were identiﬁed in both ET
and PMF patients.6 In contrast to JAK2 mutations, MPL
mutations were found less frequently in PMF and ET, and
may be present in either JAK2 mutation-positive or
mutation-negative cases.6e8 Laboratory tests for these
mutations have become standard in assessing clinically
suspected BCR-ABL1enegative MPN.
The diagnostic value of JAK2 andMPLmutations in MPN
is well established. The 2008 World Health Organization
classiﬁcation of hematopoietic neoplasms includes JAK2
mutations as diagnostic criteria in PV and JAK2 and MPL
mutations in ET and PMF.9e11 A diagnosis of PV can be
made when JAK2 V617F or exon 12 mutation is detected,
along with increased hemoglobin and low or normal levels of
erythropoietin.9 Clinically, patients with exon 12 mutations
typically present with isolated erythrocytosis and suppressed
erythropoietin, in contrast to the trilineage hyperplasia
characteristic of patients with V617Fmutation. Bone marrow
from patients with exon 12 mutation often exhibits nonspe-
ciﬁc morphology, with isolated erythroid proliferation and
absence of prominent megakaryocyte atypia and clustering.
Demonstration of exon 12 mutation in these patients is
particularly helpful for ruling out reactive erythrocytosis.5
In ET and PMF, JAK2 V617F mutations and/orMPL exon
10 mutations are present in approximately 60% to 70% of
patients, with no other well-deﬁned, recurrent JAK2 or MPL
mutations found in the remaining patients. Although detec-
tion of JAK2 V617F and MPL mutations in the appropriate
clinical settings conﬁrms the diagnosis of ET or PMF,
absence of the mutations does not rule out disease. Rare
mutations in TET2, ASXL1, IDH1/IDH2, EZH2, DNMT3A,
and CBL have been described, although the precise roles
of these mutations in the pathogenesis of ET and PMF
are unknown.12e17 Other hematological neoplasms (eg,
myelodysplastic syndrome, chronic myelomonocytic leu-
kemia, acute myeloid leukemia, and acute lymphoblastic
leukemia) may harbor JAK2 and MPL mutations in low
frequencies.18e20 Because JAK2 and MPL mutations are not
completely speciﬁc for MPN, ﬁnding of these mutations in
isolation does not warrant a diagnosis of MPN.21
Several methods have been used to detect JAK2 and MPL
mutations. Clinical laboratories may choose to use either
commercial detection kits or laboratory-developed tests. With
the availability of a broad selection of test methods, labora-
tories may ﬁnd it challenging to select the methodology and
platformmost suitable for their practice. Results fromdifferent
methods may differ with respect to analytical sensitivity,
speciﬁcity, and clinical relevance.22 There is a lack of well-
established consensus concerning common analytical issues,
such as what specimen type should be tested, whether it is
clinically relevant to differentiate heterozygous from homo-
zygous mutations, whether granulocyte enrichment should be
performed, how to interpret a low level of a positive result, and
whether quantitative results should be used and reported (and,734if yes, in which disease type and in what clinical condition).
To address these issues from the laboratory perspective, here
we present practice guidelines for JAK2 and MPL mutation
testing and reporting. The guidelines were developed by an
expert panel from the Association for Molecular Pathology
(AMP) based on the current literature and practices in the
United States and Canada. The guidelines are intended to
establish a helpful reference for laboratory professionals in
the selection of methodologies, validation of procedures, and
interpretation of results in JAK2 andMPL testing. In addition,
the guidelines can serve as a reference guide for clinical
practitioners and other health care professionals in interpre-
tation and utilization of the results. Practice guidelines also
serve to identify questions and suggest areas for future
development.
What Are the Currently Known JAK2 and MPL
Mutations?
JAK2
The JAK2 gene maps to chromosome band 9p24 and encodes
a tyrosine kinase protein composed of 1132 amino acids. It
contains three critical domains: JH1, JH2, and four-point-
one, ezrin, radixin, moesin (FERM) homolog domains.
JH1, the catalytic phosphokinase domain, is located at the
carboxyl terminus and induces phosphorylation of target
proteins. JH2, which resides upstream to JH1, is structurally
similar to JH1 but functions as a pseudokinase domain that
negatively regulates basal activity of the kinase domain and
receptor-induced activation of the catalytic function.23 The
FERM domain, which resides at the amino terminus, func-
tions as a binding protein transducing signals from JAK2 to
other transmembrane cytokine receptors (Figure 1).24
JAK2 protein kinase activity is activated by phosphor-
ylation of its kinase domain. Activation of JAK2 induces
signal transduction from both type 1 and type 2 cytokine
receptors. Constitutive activation of JAK2 by either point
mutation or fusion protein causes activation of the JAK/
STAT pathway. The activated JAK2 causes phosphoryla-
tion of STATs, which then dimerize and translocate to the
nucleus, where they regulate gene transcription. Somatic
mutations, such as V617F mutation in JH2, disrupt the
inhibitory function of the pseudokinase and thus lead to
constitutive tyrosine phosphorylation activity that promotes
cytokine hypersensitivity (UniProt, http://www.uniprot.
org/uniprot/O60674, last accessed November 28, 2012).
Although various JAK2 mutations have been reported in
exons 12, 13, 14, and 15, in the vast majority of the cases
mutations are found in codon 617, resulting in the replacement
of the amino acid valine with phenylalanine [V617F, alias
JAK2 NM_004972.3:c.1849G>T (p.Val617Phe)]. This
mutation is present in approximately 96% of PV cases, 55% of
ET cases, and 65% of PMF cases. Exon 12 mutations are far
less common, present in only approximately 3% of PV
cases. In contrast to the V617F mutation, which involvesjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Schematic representation of JAK2 gene and mutation hot spots.
Locations of reported mutations are indicated by colored triangles: red
triangles for V617F, black triangles for other SNP mutations, and blue
triangles for insertions/deletions. Representative codon numbers are marked
above exon boxes. FERM, four-point-one, ezrin, radixin, moesin domain; JH1,
kinase domain; JH2, pseudokinase domain; SH2-like, SH2-like domain.
JAK2 and MPL Mutation Guidelinesone amino acid codon, exon 12 mutations affect a larger
region, spanning codons 533 to 547. At least 27 clinically
veriﬁed exon 12 mutations have been identiﬁed to date,
including amino acid substitution, deletions, and duplica-
tions (Table 1). Additional exon 12 mutations have been
reported, but their clinical signiﬁcance is unknown.44,47 TheTable 1 JAK2 Mutations in Myeloproliferative Neoplasms
Mutation* Exon Frequency
V617F 14 w96% PV, w55% ET, w65%
V617F,C618R 14 <1% PV
V617F,C618F 14 <1% ET
V617F,D620E 14 <1% PV
L611V,V617F 14 <1% PV
C616C,V617F 14 <1% ET
D620E 14 <1% MPN
V536_I546dup 12 <1% V617F-negative PV
V536_F547dup 12 <1% V617F-negative PV
F537I,K539I 12 <1% V617F-negative PV
F537_K539delinsL 12 w10% V617F-negative PV
F537_I546dup10,F547L 12 <1% V617F-negative PV
F537_547dup 12 <1% V617F-negative PV
H538Q,K539L 12 <1% V617F-negative PV
H538D,K539L,I540S 12 <1% V617F-negative PV
H538_K539del 12 <1% V617F-negative PV
H538_K539delinsF 12 <1% V617F-negative PV
H538_K539delinsI 12 <1% V617F-negative PV
H538_K539delinsL 12 w5% V617F-negative PV
K539L 12 w10% V617F-negative PV
K539L,L545V 12 <1% V617F-negative PV
I540T 12 <1% V617F-negative PV
I540_N542delinsS 12 <1% V617F-negative PV
I540_E543delinsMK 12 w5% V617F-negative PV
I540_E543delinsKK 12 <1% V617F-negative PV
R541_E543delinsK 12 w10% V617F-negative PV
R541K,A542_G543del 12 <1% V617F-negative PV
R541_E543delinsK 12 <1% V617F-negative PV
N542_E543del 12 w40% V617F-negative PV
E543_D544del 12 w10% V617F-negative PV
D544G 12 <1% V617F-negative PV
D544_L545del 12 <1% V617F-negative PV
F547_K549delinsL 12 <1% V617F-negative PV
547insL,I540_F547dup8 12 <1% V617F-negative PV
*Mutation descriptors are not translated into the standard HGVS nomenclature
yNucleotide positions are determined based on the cited sources.
NA, not available in the original publication.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgmost frequent exon 12 mutation involves an in-frame deletion
of six nucleotides at codons 542 and 543 (N542_E543del); it is
present in approximately 40% of V617F-negative PV. Other
relatively common mutations include R541_E543delinsK
(approximately 10%), E543_D544del (approximately 10%),
F537_K539delinsL (approximately 10%), K539L (approxi-
mately 10%), H538_K539delinsL (approximately 5%), and
I540_E543delinsMK (approximately 5%).38,48,49 Mutations
in exon 13, exon 15, and exon 14 other than V617F are
exceptionally rare, and are observed in a broader variety of
disease types.50
MPL
TheMPL gene maps to chromosome band 1p34 and encodes
the thrombopoietin receptor, which binds to thrombopoietin,
the primary cytokine that regulates megakaryocyte devel-
opment and platelet production, as well as hematopoietic
stem cell homeostasis. Binding of thrombopoietin to MPLNucleotide positiony References
PMF c.1849G>T 1e4
c.1849G>T, c.1851C>T, c.1852T>C 25
c.1849G>T, c.1853G>T 25
c.1849G>T, c.1860C>A 26
c.1831T>G, c.1849G>T 27
c.1848T>C, c.1849G>T 28
c.1860C>A 29
c.1606_1638dup33 30
NA 31
c.1609T>A, c.1616A>T 32
c.1609_1616delins 5
c.1608_1640dup33 30
c.1609_1641dup33 33
c.1614C>A, c.1615A>T, c.1616A>T 5
NA 31
NA 31
c.1612_1617delins 34
c.1612_1616delins 35
c.1612_1617delins 36,37
c.1615A>T or A>C, c.1616A>T 5,37
c.1615A>T, c.1633T>G 31
c.1619T>C 32
NA 38
c.1620_1627delins 39,40
c.1619_1627delins 41
c.1622_1627delins 36,39
c.1622G>A, c.1624_1629del 42
c.1622_1627delins 34
c.1624_1629del 5
c.1627_1632del 43
c.1631A>G 44
c.1630_1635del 31
NA 45
c.1642_1644ins, c.1645_1668dup 46
, to avoid misinterpretation.
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Figure 2 Schematic representation of MPL gene and mutation hot
spots. Locations of reported mutations are indicated by colored triangles:
red triangles for W515L and W515K, and black triangles for other SNP
variant mutations. Representative codon numbers are marked above exon
boxes. CP, cytoplasmic domain; DCR-NRD, distal cytokine receptor domain-
negative regulatory domain; PCR-LBR, proximal cytokine receptor domain-
ligand binding region; TM, transmembrane domain.
Table 2 MPL Mutations in Myeloproliferative Neoplasms
Mutation* Exon Frequency
Nucleotide
positiony References
W515L or W515K 10 w5% PMF c.1544G>T 6e8
w3% ET c.1543T>A
c.1544G>A
V501A,W515L 9, 10 <1% PMF c.1502T>C 54
c.1544G>T
W501A,W515R 9, 10 <1% PMF, ET c.1502T>C 54
c.1543T>C
S505C,W515L 10 <1% ET c.1514G>A 54
c.1544G>T
S505N 10 <1% PMF, ET c.1514G>A 55,56
A506T 10 <1% PMF c.1516G>A 56
L510P 10 <1% PMF c.1529T>C 56
W515A 10 <1% ET c.1543T>G 54,56
c.1544G>C
A519T 10 <1% PMF c.1555G>A 56
S204P 4 <1% PMF c.610T>C 36
Y252H 5 <1% ET c.754T>C 53
*Mutation descriptors are not translated into the standard Human
Genome Variation Society (HGVS) nomenclature, to avoid misinterpretation.
yNucleotide positions are determined based on the cited sources.
Gong et alleads to activation of JAK2, which phosphorylates MPL and
initiates a cascade of downstream signaling events that
regulate cell survival, proliferation, and differentiation.51
Mutations of theMPL gene occur in BCR-ABL1enegative
MPN.6,7 The mutation W515L represents guanosine-to-
thymidine substitution in MPL at nucleotide 1544, which
leads to exchange of leucine for tryptophan. The mutation
results in impaired function of the autoinhibitory region and
subsequent ligand-independent thrombopoietin receptor
activation.52 This then leads to subsequent activation of
downstream tyrosine kinases and activation of transcription
factors STAT3 and STAT5, which in turn leads to trans-
formation of hematopoietic cells into cytokine-independent
clones, resulting in megakaryocytic hyperplasia and
marrow ﬁbrosis. The Y252H mutation, which is located in
the extracellular domain of MPL, confers hypersensitivity to
thrombopoietin and increases the generation of megakaryo-
cyte colonies in vitro and leads to increased thrombopoietin
signaling and cell growth and survival.53
The majority of the MPL mutations are found in exon 10
codon 515;W515L is the most common, followed byW515K.
Overall, MPL W515L or W515K mutations are present in
patients with PMF and ET at a frequency of approximately 5%
and 3%, respectively.6e8 Other codon 515 mutations include
W515A and W515R.54 Rarely, doubleMPL mutations occur-
ring in cis of exon 10 have been identiﬁed.54Mutations in other
exons includeV501A,Y252H, and S204P (Figure 2).36,53,54 In
addition to their association with sporadic MPN, MPL muta-
tions are also associated with familial diseases. S505N muta-
tion has been associated with familial autosomal dominant
thrombocytosis.55 MPL and JAK2 mutations are not mutually
exclusive, and rare cases of concurrent MPL mutation and
JAK2 V617F mutation have been reported.7,8 Clinically veri-
ﬁedMPL mutations are listed in Table 2.
When Should JAK2 and MPL Mutational Analysis
Be Performed?
Screening
The usual indications for JAK2 mutation testing include
unexplained polycythemia, neutrophilia, or thrombocytosis
(when secondary causes have been ruled out), because each
may represent aMPN57 (Table 3). Other indications for JAK2736mutation analysis include splanchnic vein thrombosis and the
provisional entity refractory anemia with ring sideroblasts
and thrombocytosis (RARS-T). Of patients with splanchnic
vein thrombosis, 31% were found to have associated JAK2
mutations and often had a latent MPN, with the most
common site of thrombosis occurring in the portal venous
system.59 Similarly, nearly one third of patients with
RARS-T were found to have a JAK2 mutation.60
After secondary causes of polycythemia have been ruled
out, JAK2 analysis (ﬁrst for exon 14 V617F, and then, if
ﬁndings are negative, for exon 12) is indicated to support the
diagnosis of PV. Ideally, JAK2 analysis for investigating the
cause of neutrophilia and thrombocytosis would follow
a determination of the absence of theBCR-ABL1 translocation
t(9;22). In practice, however, clinicians ﬁnd it easier to order
both the BCR-ABL1 and the JAK2 assays at the same time in
screening peripheral blood. There is no difference in analyt-
ical performance using peripheral blood or bone marrow
samples for testing for JAK2mutations, because granulocytes
constitute the predominant population in both specimens.61
MPL mutation analysis is not indicated in the consid-
eration of PV, because no MPL mutations have been
described for this entity. The use of MPL analysis is best
considered after pathology review of a bone marrow biopsy
and aspirate. If a diagnosis of PMF or ET is entertained,
then MPL analysis should be performed in the setting of
a negative JAK2 V617F assay, if required to meet World
Health Organization diagnostic criteria.10,11
Follow-Up Testing
The role of follow-up testing for JAK2 and MPL mutations
after therapy is not clearly established. Quantitative real-jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 Indications for JAK2 and MPL Mutation Testing
Mutation and indications
JAK2 V617F
Granulocytosis (especially BCReABL1 negative), no active
infection or inﬂammation
Erythrocytosis, with normal or low erythropoietin
Thrombocytosis, with common reactive etiologies ruled out
Increased bone marrow ﬁbrosis, excluding inﬁltration by
lymphoma or carcinoma
Splenomegaly, unexplained
Splanchnic vein thrombosis
Aquagenic pruritus
JAK2 exon 12 mutations
JAK2 V617F negative, erythrocytosis with normal or low
erythropoietin
JAK2 V617F negative, post-PV bone marrow ﬁbrosis
MPL mutations
JAK2 V617F negative, suspected ET
JAK2 V617F negative, suspected PMF
Adapted from Tefferi et al.58
JAK2 and MPL Mutation Guidelinestime PCR (qPCR) testing for monitoring JAK2 V617F allele
burden has been limited to patients enrolled in clinical trials
such as the peg-IFN-a-2a and MF-TG101348-001
trials.62,63 Although there are small-molecule inhibitors for
JAK2, such as ruxolitinib [approved by the U.S. Food and
Drug Administration (FDA) for myeloﬁbrosis], these target
the JAK2 and often the JAK1 proteins, and thus are not
speciﬁc for the V617F mutation.64 Although allele burden
has been shown to decrease after use of some inhibitors,
there is no one-to-one correlation of allele burden with
clinical response (eg, reduction in splenomegaly). Highly
sensitive qPCR for JAK2 V617F may have value in follow-
up of patients with primary and secondary myeloﬁbrosis
after allogeneic stem cell transplantation. Quantitative tests
for JAK2 V617F allele have been used to determine the
depth of clinical remission and to guide adoptive immuno-
therapy, such as donor lymphocyte infusion.65
Thus, for routine clinical practice, there is no recom-
mended schedule for follow-up JAK2 testing, whetherTable 4 Methods in Detecting JAK2 Mutations
Method Sensitivity (%) Advantage
qPCR (AS, LNA) 0.10.01 High sensitivity; quantitative
PCR (AS) 0.11 High sensitivity; simple to perf
Melting curve
analysis
510 Simple to perform; semiquantit
low cost
Pyrosequencing 510 Simple to perform; quantitative
low cost
RFLP 110 Low cost
Sanger sequencing 20 Detects all mutations; bidirecti
confirmation
AS, allele-speciﬁc; LNA, locked nucleic acid; RFLP, restriction fragment length
The Journal of Molecular Diagnostics - jmd.amjpathol.orgqualitative or quantitative. There is a dearth of follow-up
information for MPL mutation analysis, likely because of
the low number of cases identiﬁed to date.
Which Methodologies Are Used to Detect JAK2
and MPL Mutations?
Although there are no FDA-cleared tests, a number of
methods have been developed for detecting JAK2 V617F
mutation. Traditional Sanger sequencing has been used
extensively, but it has relatively poor sensitivity. Other
methods used to detect V617F include restriction fragment
length polymorphism, denaturing high-performance liquid
chromatography, high-resolution melting-curve analysis,
pyrosequencing, and various allele-speciﬁc PCR systems
with electrophoretic analysis of the products. Most of these
methods typically do not achieve sensitivities of less than
5% of alleles (Table 4).
The most widely used methods for the detection of V617F
involve allele-speciﬁc qPCR. These methods easily achieve
analytical sensitivities of1%mutant alleles. Allele-speciﬁc
qPCR also allows for quantiﬁcation of the mutant as
a percentage of all of the JAK2 alleles, as an estimate of
disease burden. Using standard curves for both the wild-type
and mutant forms, it is possible to perform this calculation;
however, there is no standardization for measuring quantity.
The clinical utility of quantiﬁcation of V617F has not yet
been established. A limitation of allele-speciﬁc qPCR is that,
in many cases, signal is generated in the mutant PCR reaction
at high CT counts even for known negative samples. In this
situation, it is necessary for the laboratory to establish the
minimal amount of signal needed to conﬁdently call a sample
positive.
There are no standard methods for detecting the rare JAK2
mutations, nor forMPLmutations. Direct Sanger sequencing
or pyrosequencing has been used for assessment of JAK2 and
MPL mutations. Some published methods screen for muta-
tions using denaturing high-performance liquid chromatog-
raphy or high-resolution melting-curve analysis, followed byDisadvantage References
Detects only target mutations 66e69
orm Detects only target mutations; not
quantitative
4,70,71
ative; Detects target mutation only; moderate
to low sensitivity; poor reproducibility
in lowþ samples
22,32,70,72
; Detects target mutation only; relatively
low sensitivity
73
Relatively low sensitivity; requires
post-PCR manipulation; unreliable
in lowþ samples; not quantitative.
22,74
onal Low sensitivity; time-consuming; not
quantitative
1e4
polymorphism.
737
Gong et aldirect sequencing to conﬁrm that a mutation is present.75,76
Higher analytical sensitivity may be achieved by using
clamped PCR, followed by nucleotide sequencing.77 Tradi-
tional allele-speciﬁc PCR and allele-speciﬁc qPCR assays
have also been used, but these assays are limited to assessing
speciﬁc mutations. With less common mutations, it is not
clear what level of analytical sensitivity is needed.
Intellectual property restrictions may inﬂuence the choice
of a JAK2V617F assay, given that Ipsogen (Marseille, France)
acquired a worldwide license on testing for this mutation in
2006. (Ipsogen became Qiagen Marseille in 2013.) Limita-
tions of the Ipsogen qualitative assay (MutaScreen assay)were
highlighted in a report that described two MPNs containing
variant JAK2 mutations, each with the typical codon 617
(1849G>T)mutation, and in one case an additional codon 617
(1851C>T) substitution and a codon 618 (1852T>C) muta-
tion, and in the other case an additional codon 618 (1853G>T)
mutation.25 These two cases gave no signal and a wild-type
result, respectively, by the Ipsogen assay, but were detected
as abnormal by melting curve analysis and subsequent Sanger
sequencing. In principle, the presence of additional exon 14
mutations can interfere with binding of primers and probes in
allele-speciﬁc assays, but such mutations are exceptionally
rare (<1% of all JAK2mutations).78 Assays that are not allele
speciﬁc, such as melting curve analysis, offer the potential to
detect rare variants, but have a signiﬁcantly lower sensitivity
(typically 5% to 10% mutant alleles). The advantages and
disadvantages of each technique, including ﬁnancial consid-
erations associated with intellectual property rights, must
therefore be carefully weighed before deciding on the type of
assay to implement (Table 4).
What Are the Technical Issues Associated with
JAK2 and MPL Mutation Testing?
Blood versus Bone Marrow
Initial testing of JAK2 andMPLmutations is most commonly
performed on peripheral blood samples. There are several
reasonswhy blood is the preferred type of specimen, including
convenience and the fact that the diagnosis of PV can in most
cases be made without a bone marrow evaluation.79 Total
white blood cells from the peripheral blood are the preferred
type of cell population for these analyses. White blood cells
can be obtained by simply performing a red blood cell lysis
procedure. Ficoll density centrifugation should be avoided,
because it depletes the granulocytic population (which carries
the mutations). Granulocyte isolation is not necessary because
granulocytes comprise approximately 45% to 75% of total
white blood cells in normal individuals, and this proportion is
even higher in peripheral blood of MPN patients. It has been
shown that granulocytic isolation achieves, on average, only
15% higher JAK2 allele burden compared with that of whole
white blood cells.80 In comparison, a 10-fold to 100-fold
increase in assay sensitivity can be easily achieved by
designing a sensitive PCR method.81,82 Unlike granulocyte738isolation, optimization in a PCR procedure does not increase
time, labor, or cost on a routine basis.
Allele Burden
The allele burden varies greatly (between 1% and 100%)
from patient to patient at the time of ﬁrst diagnosis, and low
levels of JAK2 V617F are not uncommon. With quantitative
assessment, it has been reported that approximately 20% to
30% of PV patients have less than 25% JAK2 V617F
alleles.83e85 Insensitive molecular assays would cause an
even bigger problem in ET, in which up to 75% of cases have
a JAK2 V617F level of less than 25% and a considerable
number (40% of cases) have a JAK2 V617F level of less
than 10%.83 A quantitative assay or a reasonably sensitive
qualitative assay is therefore essential for capturing the cases
with low levels of the mutation. An allele burden of greater
than 50% suggests homozygosity, which is most likely to
occur in PV; it is uncommon in ET.58 A high allele burden in
PV and ET is associated with progression to myeloﬁbrosis.86
Analytical Sensitivity
Assays with adequate analytic sensitivity are required for the
sensitive detection of JAK2 V617F, because the mutation may
be present in a small fraction of the neoplastic clonal cell pop-
ulation. In a study using direct sequencing, lower frequencies of
the JAK2V617Fwere found in all three classicalMPN entities:
65% in PV, 23% in ET, and 30% in PMF.4 Re-evaluation using
more sensitive techniques revealed higher frequencies: 95%
to 97% in PV, approximately 55% in ET, and approximately
65% in PMF, suggesting that insensitive assay methods (eg,
Sanger sequencing, which has an analytic sensitivity of 20%)
generated a signiﬁcant number of false-negative results.87,88
To ensure that more than 90% of cases are detected, the
adequate analytical sensitivity of a clinical JAK2 assay should
be at least 1%.22,82,88,89 When the JAK2 V617F level of
a particular patient falls below 1%, however, caution must be
exercised, because very low levels of JAK2 V617F mutations
(usually <0.1%) have been described in peripheral blood of
unaffected individuals.90,91 An assay that detects less than 0.1%
of JAK2 allele, therefore, ismore likely to produce false-positive
results in the diagnostic setting.90 On the other hand, low levels
(1%)of themutantJAK2havebeen reported inETpatients (as
determined using allele-speciﬁc loop-mediated ampliﬁcation
assay).92 Therefore, if other World Health Organization major
and minor diagnostic criteria are met, ﬁnding such a low-
positive JAK2 mutation may still be clinically relevant. If
there is doubt, a peripheral blood or a bone marrow specimen
collected at a later timepointmaybeused to conﬁrm theﬁnding.
How Should the Results of JAK2 and MPL
Mutation Testing Be Reported?
All ﬁnal reports must address preanalytic, analytic, and
postanalytic components.93 Preanalytic components shouldjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 5 Sample Report for Quantitative JAK2 V617F Mutation Assay
Heading Report
Specimen type Peripheral blood
Clinical indication Erythrocytosis, rule out myeloproliferative neoplasm
Qualitative result JAK2 V617F mutation detected
Quantitative result 72% mutant alleles
Interpretation Positive
The following mutation was detected: JAK2 c.1849G>T (p.V617F)
This mutation is identified in >90% of PV cases and in approximately half of ET and PMF cases. This point
mutation may also be found in other myeloid malignancies.
Methodology Genomic DNA was extracted and assayed for the V617F mutation using a TaqMan allelic discrimination
assay with a FAM-labeled mutant-specific probe and a VIC-labeled wild-type specific probe. The sensitivity
of this assay is 1% JAK2 V617F mutant in a wild-type background.
JAK2 and MPL Mutation Guidelinesinclude the tissue source (eg, peripheral blood, bone mar-
row, parafﬁn-embedded tissue) and, if available, the clinical
indication for testing. The analytic components include the
analytic result (mutation detected or not detected) and
a brief description of the methodology used. The post-
analytic components include interpretive comments, if
needed. A sample report for a quantitative JAK2 V617F
assay is presented as Table 5.
For qualitative JAK2 V617F testing, the report should
clearly indicate a ﬁnal analytic result (eg, JAK2 V617F
mutation DETECTED or JAK2 V617F mutation NOT
DETECTED). The methodology summary should include
source information regarding any commercial primers and
probes used, and it must include a statement of assay
sensitivity. JAK2 Sanger sequencing assays, such as those
for exon 12 mutations, should report any detected mutations
using standard Human Genome Variation Society (HGVS)
nucleotide and amino acid nomenclature (HGVS, http://
www.hgvs.org/mutnomen, last accessed February 19,
2013). The methodology summary of sequencing assays
should clearly state the regions covered by the assay. An
interpretive comment should be included, indicating
whether the observed mutation has been previously reported
in MPNs or other malignancies or whether the mutation
appears to be novel. Online databases, such as the Catalogue
of Somatic Mutations in Cancer (COSMIC; Catalogue of
Somatic Mutations in Cancer, http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic, last accessed February 19,
2013) and the Database of Single Nucleotide Poly-
morphisms (dbSNP; National Center for Biotechnology
Information, http://www.ncbi.nlm.nih.gov/snp, last accessed
February 19, 2013), are particularly useful for determining
whether an uncommon abnormality has been previously
reported. An estimate of the relative abundance of mutant to
wild-type alleles may be provided; this is especially
important for novel mutations, which could represent
previously unreported germline SNPs.
Because most laboratories offer V617F and exon 12 mu-
tations as separate tests, exon 12 mutation may be mistakenly
requested as the initial screening test instead of V617F
mutation. This error can be easily avoided by restricting exon
12 testing only to a reﬂex test. The results can be betterThe Journal of Molecular Diagnostics - jmd.amjpathol.orgclariﬁed by incorporating a disclaimer in the exon 12 test
report: This test does not include testing for themore common
JAK2 V617F (exon 14, c.1849G>T) mutation.
Reports of quantitative JAK2 V617F assays should
include a statement of qualitative results (eg, JAK2 V617F
mutation DETECTED), as well as a statement of quantita-
tive allele burden. The allele burden may be expressed as
a ratio of mutant (mut) to wild-type (wt) alleles, or more
commonly, as a percentage of mutated JAK2 alleles, cal-
culated as (JAK2mut)/(JAK2mut þ JAK2wt) 100.
If available, results of prior serial testing may be provided.
If a quantitative cutoff is used to deﬁne a positive result, this
value should be stated as part of the methodology summary,
and a limit of sensitivity must also be included. Allele
burden may also be reported in semiquantitative fashion (eg,
>50% to 75% mutant alleles). The terms heterozygous and
homozygous have been used in the literature to describe
cases with allele burdens of <50% and 50%, respectively,
but this terminology is potentially misleading. For example,
in a specimen with 40% mutant alleles, it is unclear whether
the sample is actually composed of 40% cells with a mono-
allelic mutation or 20% cells with a biallelic mutation. For
this reason, the terms heterozygous and homozygous should
generally be avoided in clinical reports.
Results of MPL assays should be reported in a similar
fashion as those described above for JAK2. Given the
diversity of known MPL mutations, the precise mutation
detected should be reported using HGVS-standard nucleo-
tide and amino acid nomenclature.
What Are the Needs for Standardization and
Proﬁciency Testing?
Standardization
There is a lack of standardization among the variety of
qualitative and quantitative methods available to detect the
range of molecular alterations in JAK2 and MPL. As of
writing, there were no kits cleared by the FDA for clinical
use in testing for JAK2 or MPL mutations; however, it is
possible that a companion diagnostic for the JAK2 V617F
mutation will be developed to detect the JAK2 mutation and739
Gong et alto quantify the response to targeted therapies. If a quantitative
assay is clinically indicated to achieve precise mutant levels or
to monitor allele burden, there will be a need for quantitative
standards to accurately quantify the allele burden and to assess
the sensitivity and dynamic range of the assay. A number
of AML cell lines are positive for JAK2 V617F, including
HEL, MB-02, MUTZ-8, SET-2, UKE-1. All except SET-2
are homozygous mutant, but some (eg, HEL) have more
than two copies of JAK2 and as such are not ideal as stan-
dards.94 Quantitative controls for the JAK2 V617F mutation
are commercially available (Horizon Discovery, Cambridge,
UK; Qiagen Marseille, Marseille, France) to serve as a quan-
titative or low-positive control. Positive controls for MPL
mutations are more difﬁcult to obtain. As reference standards
for quantitative JAK2 testing are made available, comparable
results across laboratories can be achieved in monitoring
treatment response and minimal residual disease.
Test Validation and Proﬁciency Testing
The approach to validation differs between qualitative and
quantitative assays. For a qualitative assay, the sensitivity
must be deﬁned. For a qPCR assay, the threshold for
a positive result must be determined, because of cross-
ampliﬁcation of the wild-type allele. A series of normal
DNA samples should be analyzed to derive the threshold for
a positive result. Because the allele burden varies between
MPN entities or between patients at diagnosis and after
treatment, samples with a low allelic frequency should be
included. A low-positive control should be included in each
run, to demonstrate that the assay is performing at the level
of the measured sensitivity. It may be difﬁcult to accumulate
JAK2 exon 12 orMPL mutant cases for validation, given the
low frequency of these variants.
Proﬁciency testing for JAK2 V617F is now standard, and
it is likely that MPL codon 515 mutations will be added in
the future. A proﬁciency test for JAK2 V617F is available
from the College of American Pathologists (2013 Surveys
and Anatomic Pathology Education Programs, http://www.
cap.org/apps/docs/proﬁciency_testing/2013_surveys_catalog.
pdf, last accessed November 28, 2012). Currently, testing is
based only on qualitative results, but the accuracy and
sensitivity of quantitative assays may be assessed in future
iterations.
What Is the Current State of Practice in Clinical
Laboratories for JAK2 and MPL Mutation
Testing?
In late 2010, a sample exchange for interlaboratory com-
parison of assays for MPNs was organized by the AMP. A
total of 66 specimens were shared among the 22 laboratories
that participated (18 in the United States, 2 in Canada, and 2
in Asia). One laboratory tested only a subset of the speci-
mens. The participating laboratories tested the samples
using a combination of quantitative and qualitative assays740for JAK2 mutations, and several of the laboratories also
performed MPL mutation assays.
Each laboratory was asked to provide three DNA speci-
mens: one known to be JAK2 V617F positive, one weakly
positive, and one from a patient suspected to have a MPN
but that was found to be JAK2 V617F negative. In addition,
one laboratory provided formalin-ﬁxed, parafﬁn-embedded
sections of spleen from a patient with polycythemia vera. Of
the 22 laboratories, 13 used in-house tests for JAK2 V617F
and the remaining 9 used commercial assays; 14 laborato-
ries performed only qualitative assays, 5 performed only
quantitative assays, and 3 performed both quantitative and
qualitative assays. Five laboratories also offered JAK2 exon
12 assays, two laboratories offered MPL mutation assays,
and another two provided MPL mutation results (although
their assays were still being validated). Most laboratories
reported analytical sensitivities in the 1% to 5% range; only
two laboratories indicated analytical sensitivities of less than
1%. Approximately half of the laboratories performed single
replicates, and half performed assays in duplicate.
The reported DNA concentrations for the 66 specimens
ranged from 0.3 to 318 ng/mL. Five of the samples resulted
in failed ampliﬁcations in more than one laboratory, and
these had very low DNA concentrations. Three other
samples appeared to have adequate DNA but still resulted in
failed ampliﬁcation in more than one laboratory.
Results were concordant for 26 of the 66 specimens (ie,
the same results were obtained by all participating labora-
tories), with 21 positive and 5 negative. An additional ﬁve
specimens were positive in all laboratories where results
were obtained; some of the laboratories did not obtain
a result with these specimens, most likely because of low
DNA concentration.
Discordant results were categorized as false negative if
more than 15 laboratories obtained a positive result and as
false positive if more than 15 laboratories obtained negative
results for a given specimen. The 16 specimens having a high
rate of false-negative results tended to have lower JAK2
allele burden in those laboratories doing quantitative assays,
suggesting that the false-negative results were mostly due to
assays with lower analytical sensitivity. Five laboratories had
two or more false-negative results, suggesting that the assays
of these laboratories may have been of lower sensitivity than
those of most participating laboratories. Another 16 speci-
mens yielded false-positive results. These tended to be
low positive when tested in laboratories using quantitative
assays, so it is likely that these specimens had JAK2 V617F
levels that were below the limit of detection for most labo-
ratories. However, there is a concern that some laboratories
may have had a high true false-positive rate, because one
laboratory had a positive result that was not detected by any
other laboratory. In a second example, one assay reported
a specimen positive for JAK2 V617F that was reported
negative in all other laboratories; however, that specimen
was found to have a JAK2 exon 12 mutation, which is
mutually exclusive with the V617F mutation.jmd.amjpathol.org - The Journal of Molecular Diagnostics
JAK2 and MPL Mutation GuidelinesNo consensus result was obtained with four of the spec-
imens. All of these were found to have low JAK2 V617F
allele burden when tested by quantitative assays. Interest-
ingly, some laboratories obtained positive results with all
four specimens, whereas others obtained negative results
with all four. Presumably, these results reﬂect differences in
analytical sensitivity among the participating laboratories.
For the false-negative, false-positive, and no-consensus
results, there appeared to be no correlation between the
discordant results and assay methodology.
Comparison among the 12 laboratories performing
quantitative JAK2 V617F assays was complicated by the
various ways in which the laboratories reported their results.
Most laboratories reported their results as a JAK2 V617
percentage of unmutated alleles. Two laboratories reported
results as one of six categories (78%, 50% to 78%, .,
<5%), and one laboratory reported results in three cate-
gories (homozygous, heterozygous, and low-level hetero-
zygous). For the purposes of comparison, results were
grouped as high (>50%), moderate (5% to 50%), low (2%
to 5%), and negative (<2%). One laboratory had a higher
rate of discordance than the others; it is possible that this
laboratory was truly an outlier, although it is also possible
that there were clerical errors in reporting the results to the
study. When this laboratory was excluded, there was
complete concordance for 29 specimens, 18 of which were
in the high category, 9 were in the moderate category, and 2
were in the low category. There was less reproducibility
between laboratories in the lower ranges, presumably
because of greater variance of the method in the low range.
No specimen was negative for all 12 laboratories, again
presumably reﬂecting poorer reproducibility at the low end
and possibly indicating high sensitivity (which could result
in false-positive results).
MPL mutation detection was compared among the four
participating laboratories. Two specimens were found
positive for the W515L mutation in all four laboratories.
One laboratory found a third specimen positive for W515L,
but the mutation was not detected in the other two labora-
tories that tested this specimen. One laboratory found an
S505N mutation that was not detected by the other labora-
tories. Interestingly, these last two specimens were also
found to be positive for JAK2 V617F by many of the
participating laboratories.
A number of conclusions can be reached, taking these
data together. First, overall JAK2 V617F mutation testing
was reproducible among the laboratories performing this
testing. Because there was incomplete concordance, it is
important that laboratories participate in proﬁciency testing
programs that include a wide spectrum of clinical labora-
tories. There is also reasonably good agreement among
laboratories for quantitative testing. Although such testing is
still not standard for diagnosing MPNs, the ﬁndings from
the sample exchange study provide hope that quantitative
testing will be reliable when such testing becomes standard
practice.The Journal of Molecular Diagnostics - jmd.amjpathol.orgFuture Directions for JAK2 and MPL Mutation
Testing
Targeted gene panels assessed by next-generation
sequencing are increasingly being used in clinical labora-
tories. This allows for broad multigene coverage in a single
assay, thereby interrogating all of the targets deemed rele-
vant for a particular clinical entity. Full sequencing of JAK2
and MPL, as well as other genes relevant for MPNs, may be
performed in this manner. If the clinical utility of mutations
in other genes (eg, TET2, ASXL1, and EZH2) is established
for MPNs, next-generation sequencing provides a way to
expand the scope of the assay without signiﬁcantly
increasing the work required to perform the test. Although
there is substantial interest in these technologies, nonethe-
less there are limitations, especially regarding sensitivity.
Estimates for general mutation detection indicate that
approximately 1000-fold coverage is needed for a given
base to achieve a 99% conﬁdence of detecting more than 5%
heterozygous mutant alleles.95 It may also be possible to
estimate mutant burden based on the allele frequency
calculated from next-generation sequencing data; however,
there has been only limited validation of the ability of next-
generation sequencing to make this type of estimation.
Disclaimer
The Association for Molecular Pathology (AMP) Clinical
Practice Guidelines and Reports are developed to be of
assistance to laboratory and other health-care professionals
by providing guidance and recommendations for particular
areas of practice. The Guidelines or Report should not be
considered inclusive of all proper approaches or methods, or
exclusive of others. The Guidelines or Report cannot guar-
antee any speciﬁc outcome, nor do they establish a standard
of care. The Guidelines or Report are not intended to dictate
the treatment of a particular patient. Treatment decisions
must be made based on the independent judgment of health-
care providers and each patient’s individual circumstances.
AMP makes no warranty, express or implied, regarding the
Guidelines or Report and speciﬁcally excludes any warran-
ties of merchantability and ﬁtness for a particular use or
purpose. AMP shall not be liable for direct, indirect, special,
incidental, or consequential damages related to the use of the
information contained herein.References
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